Trials Sponsors Conditions Drugs Pricing

Conditions

Attention Deficit Disorder With Hyperactivity Conduct Disorder Substance Abuse

Keywords

ADHDsubstance abuse riskAdderallfMRIADHD TreatmentMedication

Outcome Measures

Primary Outcomes (1)

Change in fMRI Measure
Bold activation change within the reward system. The contrasts in blood-oxygenation levels (BOLD) in regions of interest (ROIs).
baseline and 3 weeks post intervention

Secondary Outcomes (3)

ADHD Rating Score (ADHD RS)
Pretreatment, baseline and Post-Treatment, average 2 weeks
Total Dose of MAS-XR
average 2 weeks

Study Arms (1)

Adderall

EXPERIMENTAL

dosage = start at 0.25-0.50mg/kg, adjusted as necessary pills by mouth

Drug: Adderall

Interventions

AdderallDrug

3 weeks of Adderall

Also known as: Dextroamphetamine-Amphetamine

Adderall

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age7 Years - 12 Years

Sexall

Healthy VolunteersNo

Age GroupsChild (0-17)

You may qualify if:

General: pre-pubertal (e.g. Tanner stage 1 or 2)
age 7-12 inclusive

Sponsors & Collaborators

Jeffrey Newcorn
Otherlead
National Institute on Drug Abuse (NIDA)
NIHcollaborator

Study Sites (1)

Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States

MeSH Terms

Conditions

Attention Deficit Disorder with HyperactivityConduct DisorderSubstance-Related Disorders

Interventions

AdderallSLI381

Condition Hierarchy (Ancestors)

Attention Deficit and Disruptive Behavior DisordersNeurodevelopmental DisordersMental DisordersChemically-Induced Disorders

Results Point of Contact

Title: Iliyan Ivanov
Organization: Icahn School of Medicine at Mount Sinai

Study Officials

Jeffrey Newcorn, MD
Icahn School of Medicine at Mount Sinai
PRINCIPAL INVESTIGATOR
Iliyan Ivanov, MD
Icahn School of Medicine at Mount Sinai
PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee: Yes

Enrollment

33 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 4
Allocation: NA
Masking: NONE
Purpose: BASIC SCIENCE
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: SPONSOR INVESTIGATOR
PI Title: Professor

Study Record Dates

First Submitted

November 18, 2019

First Posted

November 20, 2019

Study Start

November 5, 2019

Brain Indices of Stimulant Treatment in Drug-Naive Youth at Risk for Substance Use Disorder

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Results Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (3)

Study Arms (1)

Adderall

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Results Point of Contact

Study Officials

Publication Agreements

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Documents

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Results Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (3)

Study Arms (1)

Adderall

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Results Point of Contact

Study Officials

Publication Agreements

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Documents

Locations